Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label multicohort study of ciltacabtagene autoleucel in multiple myeloma
MOH_2020-01-13_007471Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ciltacabtagene autoleucel in multiple myeloma (MM) (6 cohorts), sponsored by Janssen Pharmaceutical. Started Jul 2019; status: active, not recruiting.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2020-01-13_007471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-01-13_007471.